Purchase Order 75N95020P00096
Award Date
2/12/20
Potential Completion Date
2/11/21
Potential Value
$25K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Pharmaron, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
Q301 - Reference Laboratory Testing
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Louisville, KY 40202, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...
This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The contract is valued at $24,320.00 and does not have a set-aside designation. The contract is for pharmacokinetic studies of two compounds in non-naive cynomolgus monkeys, using both oral and intravenous routes of administration, with bioanalyses in plasma conducted in triplicate. This...
This firm fixed-price purchase order, valued at $78,300.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Pharmaron, Inc., a minority-owned, for-profit organization classified as a Subcontinent Asian (Asian-Indian) American owned business. The contract is for the testing of compounds to block cardiac ion channels, with a period of performance ending on November 16, 2022. Pharmaron, a global contract research organization (CRO) specializing...
This federal contract award to Pharmaron, Inc., a Minority Owned Business and For Profit Organization, was issued by the U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS). The contract, valued at $117,930.00, is a Firm Fixed Price Purchase Order to evaluate NNMT inhibitors in metabolic disorders. Pharmaron, a global contract research organization, will conduct various drug development activities...
This is a $35,600 firm fixed price purchase order contract awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct a mouse study evaluating NNMT inhibitors in high grade serous ovarian cancer. The work, which has a 12-month period of performance, involves formulating compounds, developing a mouse model, conducting efficacy studies, and analyzing samples. No set-aside...
This is a federal contract award from the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute on Drug Abuse to Pharmaron, Inc., a global contract research organization. The $281,751.22 purchase order contract is for a firm fixed price and does not have a set-aside designation. Under this contract, Pharmaron is conducting a variety of drug development activities to support the work of the NIH's National Center for Advancing Translational Sciences...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $108,000 purchase order to Pharmaron, Inc. for pharmacokinetics experiments involving forty rodents across two study arms. The one-year contract has Pharmaron performing the work in China under a firm fixed price arrangement. No additional details were provided on subcontractors or the specific NIH programs the research aims to support. The award information...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) awarded a firm fixed price purchase order contract valued at $10,440.00 to Pharmaron, Inc., a minority-owned, for-profit organization based in China. The contract is for a pharmacokinetic study of the drugs tamoxifen and neurotinib, with a period of performance running through October 9, 2023. Pharmaron has received over 30 prior prime contract awards...
This firm fixed-price purchase order was awarded by the Department of Health and Human Services' (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct testing of compounds for the blocking of cardiac ion channels. The period of performance is from August 7, 2020 to December 31, 2021, with a potential value of $24,795.00. The work is being performed in Louisville, Kentucky....
This is a $78,300.00 firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Pharmaron, Inc., a minority-owned for-profit organization. The contract is for testing compounds for the blockage of cardiac ion channels, which is a critical step in the drug development process. As a global contract research organization (CRO), Pharmaron has extensive expertise in preclinical research services, including...